Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04743115 | A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDS | unknown | Phase 1 | 66 | Shanghai Bensen Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 8, 2021 | clinicaltrials |
| NCT04740203 | Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL | unknown | Phase 1 / Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03156101 | A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects | unknown | Phase 1 / Phase 2 | 24 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT03265106 | A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects | unknown | Phase 1 / Phase 2 | 20 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04204161 | A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma | unknown | Phase 1 | 30 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT02546739 | Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL | unknown | Phase 1 | 100 | Beijing Doing Biomedical Co., Ltd.INDUSTRY | 1 | Jan 26, 2021 | clinicaltrials |
| NCT04723901 | Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia(CAR-T) | unknown | Phase 1 / Phase 2 | 20 | Shenzhen University General HospitalOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT04723914 | Dual Target CAR-T Cells in B-cell Lymphoma(CAR-T) | unknown | Phase 1 / Phase 2 | 20 | YuLiOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT04296461 | Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma | unknown | Phase 1 | 20 | UWELL BiopharmaINDUSTRY | 1 | Jan 22, 2021 | clinicaltrials |
| NCT03271515 | Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL | unknown | Phase 1 | 20 | Beijing Doing Biomedical Co., Ltd.INDUSTRY | 1 | Jan 20, 2021 | clinicaltrials |
| NCT03840317 | Senl_1904A and Senl_1904B Chimeric Antigen Receptor (CAR) T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia | unknown | Phase 1 | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04480788 | CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study | unknown | Phase 1 | 9 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jan 6, 2021 | clinicaltrials |
| NCT04653649 | CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. | unknown | Phase 1 / Phase 2 | 30 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04601181 | Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies | unknown | Phase 1 | 20 | Fundamenta Therapeutics, Ltd.INDUSTRY | 1 | Dec 1, 2020 | clinicaltrials |
| NCT04516551 | Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT | unknown | Phase 1 | 18 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT03559439 | CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies | unknown | Phase 1 | 9 | Shanghai Tong Ren HospitalOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT02772198 | T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies | unknown | Phase 1 / Phase 2 | 300 | Sheba Medical CenterOTHER_GOV | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03921879 | Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma | unknown | Phase 1 | 50 | Oncotartis, Inc.INDUSTRY | 1 | Oct 23, 2020 | clinicaltrials |
| NCT03083054 | Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 5 | University of Campinas, BrazilOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT03716856 | Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma | unknown | Phase 1 | 11 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT04221971 | NK Cell Infusion for Patients With Acute Myeloid Leukemia | unknown | Phase 1 | 10 | Peking University People's HospitalOTHER | 1 | Oct 1, 2020 | clinicaltrials |
| NCT03711864 | Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma | unknown | Phase 1 | 15 | Peking Union Medical College HospitalOTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT04004637 | CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia | unknown | Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 28, 2020 | clinicaltrials |
| NCT04554381 | Assesment of JL1 Expression in Acute Leukemia | unknown | Phase 1 | 50 | Assiut UniversityOTHER | 0 | Sep 18, 2020 | clinicaltrials |
| NCT02503033 | A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies | unknown | Phase 1 | 78 | Hutchison Medipharma LimitedINDUSTRY | 1 | Sep 11, 2020 | clinicaltrials |
| NCT04537442 | Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 10 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT04486872 | An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection | unknown | Phase 1 | 18 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 26, 2020 | clinicaltrials |
| NCT04500431 | Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM | unknown | Phase 1 | 10 | Shanghai Tongji Hospital, Tongji University School of MedicineOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT04500561 | YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial | unknown | Phase 1 / Phase 2 | 28 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Aug 5, 2020 | clinicaltrials |
| NCT03778619 | MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin | unknown | Phase 1 / Phase 2 | 9 | GC Cell CorporationINDUSTRY | 1 | Jul 28, 2020 | clinicaltrials |
| NCT04275583 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule | unknown | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04272957 | A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms | unknown | Phase 1 | 75 | Hutchison Medipharma LimitedINDUSTRY | 1 | Jun 16, 2020 | clinicaltrials |
| NCT04120350 | R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL:a Multicenter Phase Ib/II Stuty(REMLA) | unknown | Phase 1 / Phase 2 | 47 | Peking Union Medical College HospitalOTHER | 1 | Jun 5, 2020 | clinicaltrials |
| NCT04351022 | CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapesd or Refractory Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT04337606 | Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT02951728 | Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma(DR-CHOP) | unknown | Phase 1 / Phase 2 | 58 | Ruijin HospitalOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT04295018 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | unknown | Phase 1 | 10 | Peking Union Medical College HospitalOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT03051841 | CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma | unknown | Phase 1 | 18 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Feb 24, 2020 | clinicaltrials |
| NCT03150316 | CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma | unknown | Phase 1 | 18 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Feb 24, 2020 | clinicaltrials |
| NCT01619761 | NK Cells in Cord Blood Transplantation | unknown | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT04206943 | Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL(ISIKOK-19) | unknown | Phase 1 / Phase 2 | 24 | Acibadem UniversityOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT03015922 | Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma(MUKeleven) | unknown | Phase 1 | 4 | University of LeedsOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT04154709 | CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 15 | Kai Lin Xu; Jun Nian ZhengOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT04163575 | Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL | unknown | Phase 1 / Phase 2 | 100 | Kecellitics Biotech Company LtdINDUSTRY | 0 | Dec 23, 2019 | clinicaltrials |
| NCT04196205 | Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 12, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04194931 | Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 | 20 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 11, 2019 | clinicaltrials |
| NCT03720496 | Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy | unknown | Phase 1 | 6 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 9, 2019 | clinicaltrials |
| NCT03110640 | Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma | unknown | Phase 1 | 20 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Nov 27, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Feb 8, 2021source: clinicaltrials